Crestor Patent Settlement Allows Actavis Generic Entry In May 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
The agreement permits Actavis to launch its generic version of AstraZeneca’s Crestor 67 days before the patent on the cholesterol-lowering drug expires in return for paying AstraZeneca 39% of its net sales during this period; Actavis may also launch its alternative zinc salt formulation of Crestor at the same time.
You may also be interested in...
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few weeks on the US market to surpass total sales of the PCSK9 inhibitors to date.
Keeping Track: FDA Approves Briviact, Refuses To File Firdapse, Rejects Remune
The latest drug development news and highlights from our FDA Performance Tracker.
FDA's NDA And BLA Approvals
Original new drugs and biologics recently approved by FDA.